LAUSR

I read with interest the detailed literature review on the management of Parkinson’s disease during pregnancy by Young and colleagues. As the authors pointed out, there is a paucity of robust evidence to guide medication management in Parkinson’s disease during pregnancy. However, the authors appeared to have omitted amantadine in their review. Although it is not the most commonly used medication in Parkinson’s disease, amantadine has perhaps slightly stronger evidence to suggest potential teratogenicity and increased risk of miscarriage and hence should be avoided in women who are trying to conceive or in pregnant women. This was highlighted in another recent systematic review performed by Seier and Hillier, which was also referenced by Young and colleagues in their article.